Washington, DC – American researchers have developed a new experimental nasal spray vaccine for tuberculosis (TB) that uses DNA technology.
Animal trials have shown promising results in enhancing the effectiveness of traditional treatments for the disease.
Promising results in animal trials
The study, conducted by researchers from Johns Hopkins University School of Medicine and the Bloomberg School of Public Health,
showed that using the vaccine in conjunction with standard anti-tuberculosis drugs accelerated the eradication of the bacteria.
It also reduced lung infections and lowered the likelihood of reinfection after treatment.
The researchers noted that the findings represent a significant
advance in efforts to develop more effective treatments for tuberculosis.
Targeting treatment-resistant bacteria
The research team explained that the vaccine targets a type of tuberculosis bacteria known as “drug-resistant” or “persistent” TB.
This strain can survive in the body despite antibiotic treatment.
Therefore, it is one of the main reasons for the persistence or recurrence of the infection after treatment has ended.
The researchers hope that this approach will improve the chances of completely eradicating the disease.
They also hope to reduce relapse rates.
Further studies before human trials
The study, published in the peer-reviewed Journal of Clinical Investigation,
confirmed that the results achieved in mouse trials represent
a significant step toward developing an effective therapeutic vaccine.
However, it emphasized the need for further studies and research
before moving to clinical trials in humans to ensure the vaccine’s safety and efficacy.
